Selecta is actively seeking partnerships including in-licensing and out-licensing opportunities that would be consistent with our product and business strategy.
and research collaboration opportunities exist for our Synthetic Vaccine
Particles (SVP™) programs. Areas of interest include vaccines and
immunotherapies including rare diseases, autoimmunity, allergies,
transplantation, cancer, infections, and respiratory diseases. Selecta is also looking for in-licensing opportunities that are coordinated with our Moscow, Russia offices. Selecta Russia has access to development capabilities that enable us to efficiently conduct comprehensive proof of concept studies.
Sanofi and Selecta are collaborating to develop up to three tolerogenic immunotherapies in the area of allergies.
Click here to learn more about this collaboration.
In 2011, Selecta was awarded a subcontract by Science Applications International Corporation (SAIC) to develop a targeted antigen-specific synthetic vaccine particle product for malaria. Part of a larger US Federal Government initiative to develop and commercialize novel therapeutics and vaccines for malaria, Selecta's development efforts will be funded under SAIC's prime contract (number N01.AI.05421) with the National Institutes of Allergy and Infectious Diseases' (NIAID)Division of Microbiology and Infectious Diseases (DMID), which is part of the National Institutes of Health. Click here to learn more about this collaboration.
In 2014, Selecta secured a $8.1 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH) based on the data from Selecta Phase 1 clinical trial. The initial clinical study was funded in part by a $3 million grant from NIDA which was awarded to Selecta in 2010. These $11.1 million in grant funding from NIDA are aimed at advancing the development of a therapeutic vaccine for the treatment of smoking cessation and relapse prevention.
In 2011, Selecta formed a research collaboration with The Juvenile Diabetes Research Foundation (JDRF) to support the development of targeted synthetic vaccines for the induction of antigen-specific immune tolerance for treatment of patients with juvenile diabetes (type 1 or insulin dependent diabetes mellitus), an autoimmune disorder. Click here to learn more about this collaboration.
Since 2013 Selecta is collaborating with the Bill and Melinda Gates foundation to develop a novel dual action vaccine for the prevention of Malaria.
For further information about Selecta and the company's partnering and collaboration opportunities, please contact email@example.com.